TITLE

Is the End Coming for Embryonic Stem Cells?

AUTHOR(S)
Cook, Michael
PUB. DATE
January 2012
SOURCE
Australasian Science;Jan/Feb2012, Vol. 33 Issue 1, p48
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article looks at the implications of the cancellation of clinical trials for embryonic stem cell research in favour of adult stem cells. An overview of the debate over the ethical aspects of embryo research, therapeutic cloning and embryonic stem cells is provided. Biotechnology firm Geron has stopped all its embryonic stem cell research to focus on cancer drugs. It notes that in terms of clinical trials, adult cells are way ahead of embryonic stem cells.
ACCESSION #
70841319

 

Related Articles

  • Embryonic Stem-cell Therapy.  // PN;Apr2009, Vol. 63 Issue 4, p20 

    The article reports on the plans of Geron Corp. for a preliminary study on the safety of human embryonic stem cells (hESC) transplantation to patients with spinal cord injury (SCI). The biotechnology firm proposes to recruit patients with thoracic T3-10 injuries sustained within 7-14 days....

  • "CIRM Awards $25 Mln To Support Spinal-Cord Injury Trial, $37.7 Mln for Basic Stem-Cell Science".  // Biomedical Market Newsletter;5/9/2011, p143 

    The article reports that the Governing Board of the California Institute for Regenerative Medicine (CIRM), the State Stem Cell Agency, has approved a grant worth 25 million dollars to support the first U.S. Food & Drug Administration (FDA)-approved clinical trial based on cells derived from...

  • The Whole World Is Watching. Kalb, Claudia // Newsweek (Pacific Edition);3/30/2009 (Pacific Edition), Vol. 153 Issue 13, p40 

    This article reports that the first clinical trials for embryonic-stem-cell therapy in human patients with spinal-cord injuries will begin in the U.S. in the summer of 2009. U.S. President Barack Obama has given an executive order that lifts restrictions on this type of research. The California...

  • The Whole World Is Watching. Kalb, Claudia // Newsweek;3/30/2009, Vol. 153 Issue 13, p44 

    This article reports that the first clinical trials for embryonic-stem-cell therapy in human patients with spinal-cord injuries will begin in the U.S. in the summer of 2009. U.S. President Barack Obama has given an executive order that lifts restrictions on this type of research. The California...

  • The Whole World Is Watching. Kalb, Claudia // Newsweek (Atlantic Edition);3/30/2009 (Atlantic Edition), Vol. 153 Issue 13, p44 

    This article reports that the first clinical trials for embryonic-stem-cell therapy in human patients with spinal-cord injuries will begin in the U.S. in the summer of 2009. U.S. President Barack Obama has given an executive order that lifts restrictions on this type of research. The California...

  • THE ESSENTIAL Guide to Stem Cells. Svoboda, Elizabeth // Popular Science;Jun2009, Vol. 274 Issue 6, p60 

    The article presents a collection of facts and information regarding stem cell research. It is noted how having the ban on U.S. funding for embryonic stem cell research lifted by U.S. President Barack Obama will improve the science. The first clinical trial of embryonic stem cells, being done by...

  • Geron Seeks $100M in 'Long-Term' Funding. Wall, Tom // BioWorld Today;12/8/2010, Vol. 21 Issue 236, p1 

    This article reports on the public offering launched by Geron on December 2, 2010 that could raise as much as 100 million U.S. dollars. Proceeds from the offering will be used for clinical trials, clinical development of product candidates and general corporate purposes. A total of 17.4 million...

  • Geron Soars as First ESC Trial Clears FDA Hurdle.  // Bioworld Week;2/2/2009, Vol. 17 Issue 5, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the Phase 1 clinical trial of Geron Corp.'s GRNOPCI human embryonic stem cells. Accordingly, Geron president and chief executive officer Thomas Okarma stressed that the approval has surprised everyone which pave...

  • Geron Presents Data from GRNOPC1 Trial at International Conferences on Spinal Cord Medicine and Rehabilitation.  // Biomedical Market Newsletter;6/9/2011, p226 

    The article reports on the two presentations by Geron Corp. regarding its Phase I clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury. It states that results on the first two patients were presented at the 2011 International Conference on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics